艾意凯咨询：2023提高对肿瘤相关终点的理解度、接受度和使用度白皮书（英文版）（27页）.pdf

1、Improving the understanding,acceptance and use of oncologyrelevant endpoints in HTA body/payer decision-makingWHITE PAPERPROMISQLQ-BR23OSProgression-free survivalMinimal/measurable residual diseaseComplete responseDuration of responseTIME TO METASTASISTime to next treatmentMETASTASIS-FREE SURVIVALRe

2、lapse-free survivalEvent-free survivalDISEASE FREE SURVIVALTIME TO PROGRESSIONDISEASE-SPECIFIC BIOMARKERSClinical benefit rateDisease control ratePathological complete responseOVERALL RESPONSE RATEPartial responseMD Anderson Symptom InventorySF-36FACT-GEQ-5DQLQ-C30NSCLC-SAQQLQ-LC13FACT-CQLQ-CR2PDQSE

3、PTEMBER 20232|Improving the understanding,acceptance and use of oncologyrelevant endpoints in HTA body/payer decision-makingSEPTEMBER 2023Improving the understanding,acceptance and use of oncologyrelevant endpoints in HTA body/payer decision-makingThis thought piece has been developed as part of an

4、EFPIA project to drive awareness of the use of oncology-relevant endpoints in HTA body/payer decision-making.Oncology-relevant endpoints refer to all endpoints used in oncology clinical trials to measure outcomes relevant to patients.These can include,in addition to overall survival,patient-reported

5、 outcomes as well as progression-free survival in some metastatic settings,pathological complete response or event-free survival in early oncology settings.The thought piece was written with the support of L.E.K.Consulting and was informed by a literature review as well as 13 qualitative interviews

6、with clinicians,patient advocates and former HTA bodies/payers to better understand the value of oncology-relevant endpoints and the challenges facing their adoption.The findings were discussed and refined at three roundtables with the projects sounding board.CONTENTSCONTENTS3|Improving the understa